Replies to post #360827 on Amarin Corp Plc (AMRN)

[lizzy241]

raf, thanks for script numbers, status quo. Better than going down.

[ralphey]

gV now = V - this is direct evidence of infringement imho - since 90% of V's market is CAD - how can any thinking judge not view this as infringement is beyond me ....

[rafunrafun]

Scripts for week ending November 19, 2021

Overall drug TRx: n/a

Vascepa
TRx 78,736; -0.8% (-614) w/w; -1.9% y/y
NRx 35,425; -1.5% (-557) w/w; -6.3% y/y
Ref 43,311; -0.1% (-57) w/w; +2.0% y/y

Lovaza (Generic & Brand)
TRx 63,465; +1.3% (+785) w/w; +1.0% y/y
NRx 31,117; +1.0% (+312) w/w; -5.8% y/y
Ref 32,348; +1.5% (+473) w/w; +8.6% y/y

Generic Vascepa
TRx 21,818; -0.6% (-132) w/w; As % of total V: 21.7%
NRx 12,122; -2.6% (-325) w/w; As % of total V: 25.5%
Ref 9,686; +2.0% (+192) w/w; As % of total V: 18.3%

Generic Vascepa by Manufacturer
Hikma - TRx 13,731 (+1,000); Generic share 62.9%; Total V share 13.7%
Reddy - TRx 8,086 (-1,133); Generic share 37.1%; Total V share 8.0%

Vascepa + Generic Vascepa
TRx 100,553; -0.7% (-747)
NRx 47,547; -1.8% (-882)
Ref 53,007; +0.3% (+135)